التفاصيل البيبلوغرافية
| العنوان: |
Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands ; Galantamine of rivastigmine pleister. Een beschrijvend onderzoek op een geheugenpolikliniek in Nederland |
| المؤلفون: |
Wouters, C.J., L. Dautzenberg, L., Thissen, A., Dautzenberg, P.L.J. |
| المصدر: |
Tijdschrift voor Gerontologie en Geriatrie; No. 3 (2010) ; Tijdschrift voor Gerontologie en Geriatrie; Nr 3 (2010) ; 1875-6832 ; 0167-9228 |
| بيانات النشر: |
Radboud University Press |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
rivastigmine transdermale pleister, galantamine, geheugenpolikliniek, head to head study, ziekte van Alzheimer, Rivastigmine transdermal patch, Memory clinic, Alzheimer’s disease, treatment |
| الوصف: |
Objectives: Since January 2008 in The Netherlands, two cholinesterase inhibitors,oral galantamine and rivastigmine transdermal patch, are registeredas a one-day symptomatic treatment for Alzheimer’s disease. As no head tohead study was performed yet, the objective of this study was to describethe daily practice of oral galantamine and rivastigmine transdermal patch ina real life population of a memory clinic of a suburban teaching hospital inThe Netherlands. Methods: A randomized open label study in 84 ambulantAlzheimer’s patients with at least 6 months follow-up and treated eitherwith oral galantamine (group G) or rivastigmine transdermal patch (groupR). Data collection included patients’ demographic and disease variables.Adverse events were collected and, in case of interruption of the primarytreatment, the alternative treatment was registered. Results: Serious adverseevents did not occur. In group G respectively group R adverse events occurredin 20 patients (50%) and 18 patients (41%). No difference occurred inthe frequency of nausea or vomiting. In group R more patients noted dermatologicaladverse events. In group G respectively group R medication wasstopped in 12 patients (30%) and 14 patients (32%). However, compared togroup G after stopping the treatment in group R more patients received anew anti-dementia medication (respectively 11 patients (79%) and 4 patients(33%)) (χ2(1) = 5.418, p = .026). Conclusion: Despite different forms,the use of oral galantamine and rivastigmine transdermal patch showedneither difference in the frequency of adverse events neither in the frequencyof stopping primary treatment. However, compared to oral galantamineuse, rivastigmine transdermal patch resulted in more dermatologicaladverse events and after stopping rivastigmine transdermal patch, new anti-dementia medication or form was more often started. More research isurgently needed. ; Doel van onderzoek In Nederland zijn vanafjanuari 2008 twee eenmaaldaags toe te dienencholinesteraseremmers geregistreerdvoor de ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
Dutch; Flemish |
| العلاقة: |
https://platform.openjournals.nl/tgg/article/view/16224/17658Test; https://platform.openjournals.nl/tgg/article/view/16224Test |
| الإتاحة: |
https://platform.openjournals.nl/tgg/article/view/16224Test |
| رقم الانضمام: |
edsbas.B325FF23 |
| قاعدة البيانات: |
BASE |
